• Home
  • About RSIS
    • Introduction
    • Building the Foundations
    • Welcome Message
    • Board of Governors
    • Staff Profiles
      • Executive Deputy Chairman’s Office
      • Dean’s Office
      • Management
      • Distinguished Fellows
      • Faculty and Research
      • Associate Research Fellows, Senior Analysts and Research Analysts
      • Visiting Fellows
      • Adjunct Fellows
      • Administrative Staff
    • Honours and Awards for RSIS Staff and Students
    • RSIS Endowment Fund
    • Endowed Professorships
    • Career Opportunities
    • Getting to RSIS
  • Research
    • Research Centres
      • Centre for Multilateralism Studies (CMS)
      • Centre for Non-Traditional Security Studies (NTS Centre)
      • Centre of Excellence for National Security (CENS)
      • Institute of Defence and Strategic Studies (IDSS)
      • International Centre for Political Violence and Terrorism Research (ICPVTR)
    • Research Programmes
      • National Security Studies Programme (NSSP)
      • Studies in Inter-Religious Relations in Plural Societies (SRP) Programme
    • Future Issues and Technology Cluster
    • [email protected] Newsletter
    • Other Research
      • Science and Technology Studies Programme (STSP) (2017-2020)
  • Graduate Education
    • Graduate Programmes Office
    • Overview
    • MSc (Asian Studies)
    • MSc (International Political Economy)
    • MSc (International Relations)
    • MSc (Strategic Studies)
    • NTU-Warwick Double Masters Programme
    • PhD Programme
    • Exchange Partners and Programmes
    • How to Apply
    • Financial Assistance
    • Meet the Admissions Team: Information Sessions and other events
    • RSIS Alumni
  • Alumni & Networks
    • Alumni
    • Asia-Pacific Programme for Senior Military Officers (APPSMO)
    • Asia-Pacific Programme for Senior National Security Officers (APPSNO)
    • International Strategy Forum-Asia (ISF-Asia)
    • SRP Executive Programme
    • Terrorism Analyst Training Course (TATC)
  • Publications
    • RSIS Publications
      • Annual Reviews
      • Books
      • Bulletins and Newsletters
      • Commentaries
      • Counter Terrorist Trends and Analyses
      • Commemorative / Event Reports
      • IDSS Paper
      • Interreligious Relations
      • Monographs
      • NTS Insight
      • Policy Reports
      • Working Papers
      • RSIS Publications for the Year
    • Glossary of Abbreviations
    • External Publications
      • Authored Books
      • Journal Articles
      • Edited Books
      • Chapters in Edited Books
      • Policy Reports
      • Working Papers
      • Op-Eds
      • External Publications for the Year
    • Policy-relevant Articles Given RSIS Award
  • Media
    • Great Powers
    • Sustainable Security
    • Other Resource Pages
    • Media Highlights
    • News Releases
    • Speeches
    • Vidcast Channel
    • Audio/Video Forums
  • Events
  • Giving
  • Contact Us
Facebook
Twitter
YouTube
RSISVideoCast RSISVideoCast rsis.sg
Linkedin
instagram instagram rsis.sg
RSS
  • Home
  • About RSIS
      • Introduction
      • Building the Foundations
      • Welcome Message
      • Board of Governors
      • Staff Profiles
        • Executive Deputy Chairman’s Office
        • Dean’s Office
        • Management
        • Distinguished Fellows
        • Faculty and Research
        • Associate Research Fellows, Senior Analysts and Research Analysts
        • Visiting Fellows
        • Adjunct Fellows
        • Administrative Staff
      • Honours and Awards for RSIS Staff and Students
      • RSIS Endowment Fund
      • Endowed Professorships
      • Career Opportunities
      • Getting to RSIS
  • Research
      • Research Centres
        • Centre for Multilateralism Studies (CMS)
        • Centre for Non-Traditional Security Studies (NTS Centre)
        • Centre of Excellence for National Security (CENS)
        • Institute of Defence and Strategic Studies (IDSS)
        • International Centre for Political Violence and Terrorism Research (ICPVTR)
      • Research Programmes
        • National Security Studies Programme (NSSP)
        • Studies in Inter-Religious Relations in Plural Societies (SRP) Programme
      • Future Issues and Technology Cluster
      • [email protected] Newsletter
      • Other Research
        • Science and Technology Studies Programme (STSP) (2017-2020)
  • Graduate Education
      • Graduate Programmes Office
      • Overview
      • MSc (Asian Studies)
      • MSc (International Political Economy)
      • MSc (International Relations)
      • MSc (Strategic Studies)
      • NTU-Warwick Double Masters Programme
      • PhD Programme
      • Exchange Partners and Programmes
      • How to Apply
      • Financial Assistance
      • Meet the Admissions Team: Information Sessions and other events
      • RSIS Alumni
  • Alumni & Networks
      • Alumni
      • Asia-Pacific Programme for Senior Military Officers (APPSMO)
      • Asia-Pacific Programme for Senior National Security Officers (APPSNO)
      • International Strategy Forum-Asia (ISF-Asia)
      • SRP Executive Programme
      • Terrorism Analyst Training Course (TATC)
  • Publications
      • RSIS Publications
        • Annual Reviews
        • Books
        • Bulletins and Newsletters
        • Commentaries
        • Counter Terrorist Trends and Analyses
        • Commemorative / Event Reports
        • IDSS Paper
        • Interreligious Relations
        • Monographs
        • NTS Insight
        • Policy Reports
        • Working Papers
        • RSIS Publications for the Year
      • Glossary of Abbreviations
      • External Publications
        • Authored Books
        • Journal Articles
        • Edited Books
        • Chapters in Edited Books
        • Policy Reports
        • Working Papers
        • Op-Eds
        • External Publications for the Year
      • Policy-relevant Articles Given RSIS Award
  • Media
      • Great Powers
      • Sustainable Security
      • Other Resource Pages
      • Media Highlights
      • News Releases
      • Speeches
      • Vidcast Channel
      • Audio/Video Forums
  • Events
  • Giving
  • Contact Us
  • instagram instagram rsis.sg
Connect

Getting to RSIS

Map

Address

Nanyang Technological University
Block S4, Level B3,
50 Nanyang Avenue,
Singapore 639798

View location on Google maps Click here for directions to RSIS

Get in Touch

    Connect with Us

      rsis.ntu
      rsis_ntu
      rsisntu
    RSISVideoCast RSISVideoCast rsisvideocast
      school/rsis-ntu
    instagram instagram rsis.sg
      RSS
    Subscribe to RSIS Publications
    Subscribe to RSIS Events

    RSIS Intranet

    S. Rajaratnam School of International Studies Think Tank and Graduate School Ponder The Improbable Since 1966
    Nanyang Technological University Nanyang Technological University

    Skip to content

     
    • RSIS
    • Publication
    • RSIS Publications
    • Global Health Security COVID-19 and Its Impacts – Vaccine Politics: Compulsory Licensing in SE Asia?
    • Annual Reviews
    • Books
    • Bulletins and Newsletters
    • Commentaries
    • Counter Terrorist Trends and Analyses
    • Commemorative / Event Reports
    • IDSS Paper
    • Interreligious Relations
    • Monographs
    • NTS Insight
    • Policy Reports
    • Working Papers
    • RSIS Publications for the Year

    CO21067 | Global Health Security COVID-19 and Its Impacts – Vaccine Politics: Compulsory Licensing in SE Asia?
    Hannah Sworn

    23 April 2021

    download pdf
    RSIS Commentary is a platform to provide timely and, where appropriate, policy-relevant commentary and analysis of topical and contemporary issues. The authors’ views are their own and do not represent the official position of the S. Rajaratnam School of International Studies (RSIS), NTU. These commentaries may be reproduced with prior permission from RSIS and due credit to the author(s) and RSIS. Please email to Editor RSIS Commentary at [email protected].

    SYNOPSIS

    Compulsory licensing offers an attractive option for Southeast Asian governments to bypass patent protections and produce desperately needed COVID-19 vaccines for their populations while navigating the geopolitical risks of relying on Chinese vaccine donations.

    COMMENTARY

    ACCESS TO COVID-19 vaccines has become highly politicised, creating diplomatic spats such as that between the European Union and Britain and triggering a wave of export controls on medical products. Developed states have snapped up the lion’s share of high-efficacy patented vaccines produced by Pfizer, AstraZeneca and Moderna while their less-developed counterparts struggle to secure sufficient supplies for their populations.

    As developing countries lose out in the race to secure COVID-19 vaccinations, conflict over patent protection as a barrier to access to essential medicines has reared its ugly head. What policy options are available for governments in the region to secure sufficient supplies of expensive patented vaccines that have thus far been snapped up by developed states?

    Intellectual Property in the COVID-19 Era

    As of March 2021, 76% of all vaccine doses had been administered in ten — mostly high-income — countries where younger, less at-risk populations are being inoculated before vulnerable groups in developing countries. This vaccination gap increases the risk of extending the pandemic through additional waves, new strains and global economic fallout originating from countries with low vaccine coverage.

    Like many other drugs, COVID-19 vaccines are protected by patents, which — to incentivise innovation — stop an invention from being produced without permission from the patent holder for a certain period of time. However, the enforcement of property rights for essential drugs during global health crises has been a longstanding controversy, from the HIV/AIDS pandemic of the 1980s and 90s to the 2006 swine flu pandemic and now COVID-19.

    High IP protections of drugs can prevent the production of cheap but equally effective generic versions and impede access to medications in countries that cannot afford expensive branded drugs. Yet, pharmaceutical companies argue that patents are necessary to encourage invention of life-saving drugs in the first place.

    Moderna has announced that it will not enforce the patent on its vaccine in the short term. However, in the WTO, developed countries have blocked a request from over 80 developing states for an IP waiver on all COVID-19 vaccines, presumably to protect their economic interests. Similarly, the WHO’s COVID-19 technology access pool — which provides countries with access to patent-free drug technology and data — has thus far had zero contributions from pharmaceutical companies.

    The Politics of Southeast Asia’s Vaccine Dilemma

    In the midst of vaccine protectionism, China has emerged as a champion of global public goods in health, donating vaccines to 53 developing countries around the world, including millions to ASEAN members. Beijing is also partnering with Indonesian drug firm PT Bio Farma, who will manufacture enough Sinovac for 40% of Indonesia’s vaccine needs and eventually serve as a regional vaccine production hub.

    Yet, there are fears that over-reliance on Chinese vaccines will increase Beijing’s leverage to secure favourable compromises on its regional security interests, such as those in the South China Sea. This concern is amplified by the declining trust between the region’s governments and China, illustrated by the recent increase in Chinese fishing boats in waters claimed by the Philippines and a new law that authorises the Chinese Coast Guard to fire on foreign vessels in disputed waters.

    Alternative vaccines from the US and its partners may not come fast enough, putting Southeast Asian governments in a difficult position. In March the Quad — a security dialogue platform comprising the United States, Australia, Japan and India — pledged to supply one billion vaccines to Southeast Asia by the end of 2022. However, these states have a much more immediate need to vaccinate their populations to prevent further fatalities and bolster economic recovery.

    Responses to Compulsory Licensing

    The 1994 WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) drew intense criticism for impeding access to medicines by increasing the minimum IP standards for all WTO members.

    The ensuing 2001 Doha Declaration and 2003 WTO Ministerial decision gave developing countries the right to use TRIPS ‘flexibilities’ to bypass IP protections for public health and national emergencies. One of these flexibilities is compulsory licensing, which allows a country to produce, export and import a patented drug without permission from the patent holder.

    Since the onset of the COVID-19 pandemic, compulsory licensing has drawn attention as a useful tool for speeding up access to vaccines through more efficient regional production. Although pharmaceutical companies and developed states view compulsory licensing as expropriation,  Canada, Chile, Ecuador, France, Germany and Israel have all taken steps to make compulsory licensing easier since the start of the pandemic, although Israel is the only country to have issued a compulsory licence (for an early and ultimately ineffective virus treatment).

    Although compulsory licensing carries the risk of backlash from pharmaceutical companies and its administrative requirements are burdensome, Malaysia, Thailand and Indonesia have a long history with compulsory licensing. These countries have previously used compulsory licences to produce and import drugs to treat HIV/AIDS, hepatitis, cancer and cardiovascular disease.

    Compulsory Licensing in Southeast Asia?

    In 2003, Malaysia became the first Asian country to issue compulsory licenses post-TRIPS, paving the way for Thailand and Indonesia to do the same on numerous occasions between 2004 and 2012.

    Their experience is valuable given ASEAN’s commitment to information sharing on using TRIPS flexibilities to facilitate access to essential medications. These three countries in addition to the Philippines and Vietnam also have well-established domestic drugs industries with the capacity to manufacture pharmaceuticals for domestic consumption and export.

    Compulsory licensing could be a useful way for Southeast Asian states to secure vaccine access without the political consequences of reliance on China or the economic and health consequences of waiting for slow vaccine donations from the US and its partners.

    Governments can continue using Chinese vaccines in the short term while working towards producing a variety of vaccines under compulsory licenses to reduce their dependence on external parties. Whether they choose to employ this flexibility will ultimately depend on how each perceives the severity of the virus and the risks of relying on the US or China.

    About the Author

    Hannah Elyse Sworn is a Senior Analyst at the S. Rajaratnam School of International Studies (RSIS), Nanyang Technological University, Singapore. She recently co-authored “Strategic Ambiguity and the Trumpian Approach to China–Taiwan Relations” in International Affairs.

    Categories: Commentaries / Country and Region Studies / Non-Traditional Security / East Asia and Asia Pacific / Global / South Asia / Southeast Asia and ASEAN

    Last updated on 27/04/2021

    comments powered by Disqus
    "Vaccine Politics: Compulsory Licensing in SE Asia?" by Hannah Sworn
    In this podcast, Hannah Sworn, Research Analyst at RSIS, shares that compulsory licensing offers an attractive option for Southeast Asian governments to bypass patent protections and produce desperately needed COVID-19 vaccines for their populations while navigating the geopolitical risks of relying on Chinese vaccine donations.
    RSIS Commentary is a platform to provide timely and, where appropriate, policy-relevant commentary and analysis of topical and contemporary issues. The authors’ views are their own and do not represent the official position of the S. Rajaratnam School of International Studies (RSIS), NTU. These commentaries may be reproduced with prior permission from RSIS and due credit to the author(s) and RSIS. Please email to Editor RSIS Commentary at [email protected].

    SYNOPSIS

    Compulsory licensing offers an attractive option for Southeast Asian governments to bypass patent protections and produce desperately needed COVID-19 vaccines for their populations while navigating the geopolitical risks of relying on Chinese vaccine donations.

    COMMENTARY

    ACCESS TO COVID-19 vaccines has become highly politicised, creating diplomatic spats such as that between the European Union and Britain and triggering a wave of export controls on medical products. Developed states have snapped up the lion’s share of high-efficacy patented vaccines produced by Pfizer, AstraZeneca and Moderna while their less-developed counterparts struggle to secure sufficient supplies for their populations.

    As developing countries lose out in the race to secure COVID-19 vaccinations, conflict over patent protection as a barrier to access to essential medicines has reared its ugly head. What policy options are available for governments in the region to secure sufficient supplies of expensive patented vaccines that have thus far been snapped up by developed states?

    Intellectual Property in the COVID-19 Era

    As of March 2021, 76% of all vaccine doses had been administered in ten — mostly high-income — countries where younger, less at-risk populations are being inoculated before vulnerable groups in developing countries. This vaccination gap increases the risk of extending the pandemic through additional waves, new strains and global economic fallout originating from countries with low vaccine coverage.

    Like many other drugs, COVID-19 vaccines are protected by patents, which — to incentivise innovation — stop an invention from being produced without permission from the patent holder for a certain period of time. However, the enforcement of property rights for essential drugs during global health crises has been a longstanding controversy, from the HIV/AIDS pandemic of the 1980s and 90s to the 2006 swine flu pandemic and now COVID-19.

    High IP protections of drugs can prevent the production of cheap but equally effective generic versions and impede access to medications in countries that cannot afford expensive branded drugs. Yet, pharmaceutical companies argue that patents are necessary to encourage invention of life-saving drugs in the first place.

    Moderna has announced that it will not enforce the patent on its vaccine in the short term. However, in the WTO, developed countries have blocked a request from over 80 developing states for an IP waiver on all COVID-19 vaccines, presumably to protect their economic interests. Similarly, the WHO’s COVID-19 technology access pool — which provides countries with access to patent-free drug technology and data — has thus far had zero contributions from pharmaceutical companies.

    The Politics of Southeast Asia’s Vaccine Dilemma

    In the midst of vaccine protectionism, China has emerged as a champion of global public goods in health, donating vaccines to 53 developing countries around the world, including millions to ASEAN members. Beijing is also partnering with Indonesian drug firm PT Bio Farma, who will manufacture enough Sinovac for 40% of Indonesia’s vaccine needs and eventually serve as a regional vaccine production hub.

    Yet, there are fears that over-reliance on Chinese vaccines will increase Beijing’s leverage to secure favourable compromises on its regional security interests, such as those in the South China Sea. This concern is amplified by the declining trust between the region’s governments and China, illustrated by the recent increase in Chinese fishing boats in waters claimed by the Philippines and a new law that authorises the Chinese Coast Guard to fire on foreign vessels in disputed waters.

    Alternative vaccines from the US and its partners may not come fast enough, putting Southeast Asian governments in a difficult position. In March the Quad — a security dialogue platform comprising the United States, Australia, Japan and India — pledged to supply one billion vaccines to Southeast Asia by the end of 2022. However, these states have a much more immediate need to vaccinate their populations to prevent further fatalities and bolster economic recovery.

    Responses to Compulsory Licensing

    The 1994 WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) drew intense criticism for impeding access to medicines by increasing the minimum IP standards for all WTO members.

    The ensuing 2001 Doha Declaration and 2003 WTO Ministerial decision gave developing countries the right to use TRIPS ‘flexibilities’ to bypass IP protections for public health and national emergencies. One of these flexibilities is compulsory licensing, which allows a country to produce, export and import a patented drug without permission from the patent holder.

    Since the onset of the COVID-19 pandemic, compulsory licensing has drawn attention as a useful tool for speeding up access to vaccines through more efficient regional production. Although pharmaceutical companies and developed states view compulsory licensing as expropriation,  Canada, Chile, Ecuador, France, Germany and Israel have all taken steps to make compulsory licensing easier since the start of the pandemic, although Israel is the only country to have issued a compulsory licence (for an early and ultimately ineffective virus treatment).

    Although compulsory licensing carries the risk of backlash from pharmaceutical companies and its administrative requirements are burdensome, Malaysia, Thailand and Indonesia have a long history with compulsory licensing. These countries have previously used compulsory licences to produce and import drugs to treat HIV/AIDS, hepatitis, cancer and cardiovascular disease.

    Compulsory Licensing in Southeast Asia?

    In 2003, Malaysia became the first Asian country to issue compulsory licenses post-TRIPS, paving the way for Thailand and Indonesia to do the same on numerous occasions between 2004 and 2012.

    Their experience is valuable given ASEAN’s commitment to information sharing on using TRIPS flexibilities to facilitate access to essential medications. These three countries in addition to the Philippines and Vietnam also have well-established domestic drugs industries with the capacity to manufacture pharmaceuticals for domestic consumption and export.

    Compulsory licensing could be a useful way for Southeast Asian states to secure vaccine access without the political consequences of reliance on China or the economic and health consequences of waiting for slow vaccine donations from the US and its partners.

    Governments can continue using Chinese vaccines in the short term while working towards producing a variety of vaccines under compulsory licenses to reduce their dependence on external parties. Whether they choose to employ this flexibility will ultimately depend on how each perceives the severity of the virus and the risks of relying on the US or China.

    About the Author

    Hannah Elyse Sworn is a Senior Analyst at the S. Rajaratnam School of International Studies (RSIS), Nanyang Technological University, Singapore. She recently co-authored “Strategic Ambiguity and the Trumpian Approach to China–Taiwan Relations” in International Affairs.

    Categories: Commentaries / Country and Region Studies / Non-Traditional Security

    Last updated on 27/04/2021

    Back to top

    Terms of Use | Privacy Statement
    Copyright © S. Rajaratnam School of International Studies. All rights reserved.
    This site uses cookies to offer you a better browsing experience. By continuing, you are agreeing to the use of cookies on your device as described in our privacy policy. Learn more
    OK
    Latest Book
    Global Health Security COVID-19 and Its Impacts – Vaccine Politics: Compulsory Licensing in SE Asia?

    SYNOPSIS

    Compulsory licensing offers an attractive option for Southeast Asian governments to bypass patent protections and produce desperately needed COVID- ...
    more info